Japan IP Court backs Boehringer diabetes drug patents, rejects Nipro challenges
By Toko Sekiguchi ( April 30, 2026, 08:54 GMT | Insight) -- Japan’s Intellectual Property High Court upheld three Boehringer Ingelheim patents covering its diabetes drug linagliptin, rejecting challenges by generics maker Nipro and clarifying that drug patents can remain valid even without direct experimental data for every claimed use.Japan’s Intellectual Property High Court upheld three Boehringer Ingelheim patents covering its diabetes drug linagliptin, rejecting challenges by generics maker Nipro and clarifying that drug patents can remain valid even without direct experimental data for every claimed use....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.